P4 Technologies

P4 Technologies is a healthcare technology and services company that operates a suite of businesses focused on the "P4" medicine model: Predictive, Preventive, Personalized, and Participatory. The company's core operations include P4 Diagnostix, a network of specialized diagnostic laboratories; VitalAxis, a cloud-based healthcare IT platform for laboratory management; and P4 Clinical, a contract research organization (CRO) supporting clinical trials. Through its acquisition of Metamark Genetics, P4 Technologies provides advanced proteomic testing, such as the ProMark biopsy-based prognostic test for prostate cancer. Additionally, the company's P4 Therapeutics division is involved in the development of novel oncology treatments, including its lead small molecule candidate, P4-76. By integrating diagnostic data with clinical research, P4 Technologies aims to accelerate the delivery of precision medicine.